vs
网飞（NFLX）与辉瑞（PFE）财务数据对比。点击上方公司名可切换其他公司
辉瑞的季度营收约是网飞的1.4倍（$17.6B vs $12.2B），网飞净利率更高（43.1% vs -9.4%，领先52.5%），网飞同比增速更快（16.2% vs -1.2%），网飞自由现金流更多（$5.1B vs $4.5B），过去两年网飞的营收复合增速更高（13.2% vs 8.6%）
网飞是来自美国的会员制点播流媒体服务平台，主要提供不同品类的原创及引进电影、电视剧内容，业务覆盖全球众多国家和地区，支持多语言服务，致力于为全球用户提供多元优质的视听娱乐体验。
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
NFLX vs PFE — 直观对比
营收规模更大
PFE
是对方的1.4倍
$12.2B
营收增速更快
NFLX
高出17.4%
-1.2%
净利率更高
NFLX
高出52.5%
-9.4%
自由现金流更多
NFLX
多$591.1M
$4.5B
两年增速更快
NFLX
近两年复合增速
8.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.2B | $17.6B |
| 净利润 | $5.3B | $-1.6B |
| 毛利率 | 51.9% | 70.0% |
| 营业利润率 | 32.3% | -9.4% |
| 净利率 | 43.1% | -9.4% |
| 营收同比 | 16.2% | -1.2% |
| 净利润同比 | 82.8% | -501.7% |
| 每股收益（稀释后） | $1.23 | $-0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NFLXPFE
| Q1 26 | $12.2B | — | ||
| Q4 25 | $12.1B | $17.6B | ||
| Q3 25 | $11.5B | $16.7B | ||
| Q2 25 | $11.1B | $14.7B | ||
| Q1 25 | $10.5B | $13.7B | ||
| Q4 24 | $10.2B | $17.8B | ||
| Q3 24 | $9.8B | $17.7B | ||
| Q2 24 | $9.6B | $13.3B |
净利润NFLXPFE
| Q1 26 | $5.3B | — | ||
| Q4 25 | $2.4B | $-1.6B | ||
| Q3 25 | $2.5B | $3.5B | ||
| Q2 25 | $3.1B | $2.9B | ||
| Q1 25 | $2.9B | $3.0B | ||
| Q4 24 | $1.9B | $410.0M | ||
| Q3 24 | $2.4B | $4.5B | ||
| Q2 24 | $2.1B | $41.0M |
毛利率NFLXPFE
| Q1 26 | 51.9% | — | ||
| Q4 25 | 45.9% | 70.0% | ||
| Q3 25 | 46.4% | 74.9% | ||
| Q2 25 | 51.9% | 74.2% | ||
| Q1 25 | 50.1% | 79.3% | ||
| Q4 24 | 43.7% | 66.7% | ||
| Q3 24 | 47.9% | 70.3% | ||
| Q2 24 | 45.9% | 75.2% |
营业利润率NFLXPFE
| Q1 26 | 32.3% | — | ||
| Q4 25 | 24.5% | -9.4% | ||
| Q3 25 | 28.2% | 20.0% | ||
| Q2 25 | 34.1% | 20.8% | ||
| Q1 25 | 31.7% | 20.3% | ||
| Q4 24 | 22.2% | -0.1% | ||
| Q3 24 | 29.6% | 26.6% | ||
| Q2 24 | 27.2% | -0.8% |
净利率NFLXPFE
| Q1 26 | 43.1% | — | ||
| Q4 25 | 20.1% | -9.4% | ||
| Q3 25 | 22.1% | 21.3% | ||
| Q2 25 | 28.2% | 19.9% | ||
| Q1 25 | 27.4% | 21.6% | ||
| Q4 24 | 18.2% | 2.3% | ||
| Q3 24 | 24.1% | 25.2% | ||
| Q2 24 | 22.5% | 0.3% |
每股收益（稀释后）NFLXPFE
| Q1 26 | $1.23 | — | ||
| Q4 25 | $-17.14 | $-0.29 | ||
| Q3 25 | $5.87 | $0.62 | ||
| Q2 25 | $7.19 | $0.51 | ||
| Q1 25 | $0.66 | $0.52 | ||
| Q4 24 | $4.27 | $0.07 | ||
| Q3 24 | $5.40 | $0.78 | ||
| Q2 24 | $4.88 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.3B | $1.1B |
| 总债务越低越好 | $13.4B | — |
| 股东权益账面价值 | $31.1B | $86.5B |
| 总资产 | $61.0B | $208.2B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资NFLXPFE
| Q1 26 | $12.3B | — | ||
| Q4 25 | $9.1B | $1.1B | ||
| Q3 25 | $9.3B | $1.3B | ||
| Q2 25 | $8.4B | $1.6B | ||
| Q1 25 | $8.4B | $1.4B | ||
| Q4 24 | $9.6B | $1.0B | ||
| Q3 24 | $9.2B | $1.1B | ||
| Q2 24 | $6.7B | $1.1B |
总债务NFLXPFE
| Q1 26 | $13.4B | — | ||
| Q4 25 | $13.5B | — | ||
| Q3 25 | $14.5B | — | ||
| Q2 25 | $14.5B | — | ||
| Q1 25 | $14.0B | — | ||
| Q4 24 | $13.8B | — | ||
| Q3 24 | $14.2B | — | ||
| Q2 24 | $12.2B | — |
股东权益NFLXPFE
| Q1 26 | $31.1B | — | ||
| Q4 25 | $26.6B | $86.5B | ||
| Q3 25 | $26.0B | $92.8B | ||
| Q2 25 | $25.0B | $88.7B | ||
| Q1 25 | $24.0B | $90.3B | ||
| Q4 24 | $24.7B | $88.2B | ||
| Q3 24 | $22.7B | $92.3B | ||
| Q2 24 | $22.1B | $87.7B |
总资产NFLXPFE
| Q1 26 | $61.0B | — | ||
| Q4 25 | $55.6B | $208.2B | ||
| Q3 25 | $54.9B | $208.7B | ||
| Q2 25 | $53.1B | $206.1B | ||
| Q1 25 | $52.1B | $208.0B | ||
| Q4 24 | $53.6B | $213.4B | ||
| Q3 24 | $52.3B | $219.5B | ||
| Q2 24 | $49.1B | $216.2B |
负债/权益比NFLXPFE
| Q1 26 | 0.43× | — | ||
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.56× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.56× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.3B | $5.3B |
| 自由现金流经营现金流 - 资本支出 | $5.1B | $4.5B |
| 自由现金流率自由现金流/营收 | 41.6% | 25.6% |
| 资本支出强度资本支出/营收 | 1.6% | 4.8% |
| 现金转化率经营现金流/净利润 | 1.00× | — |
| 过去12个月自由现金流最近4个季度 | $11.9B | $9.1B |
8季度趋势，按日历期对齐
经营现金流NFLXPFE
| Q1 26 | $5.3B | — | ||
| Q4 25 | $2.1B | $5.3B | ||
| Q3 25 | $2.8B | $4.6B | ||
| Q2 25 | $2.4B | $-582.0M | ||
| Q1 25 | $2.8B | $2.3B | ||
| Q4 24 | $1.5B | $6.7B | ||
| Q3 24 | $2.3B | $6.7B | ||
| Q2 24 | $1.3B | $-1.8B |
自由现金流NFLXPFE
| Q1 26 | $5.1B | — | ||
| Q4 25 | $1.9B | $4.5B | ||
| Q3 25 | $2.7B | $4.0B | ||
| Q2 25 | $2.3B | $-1.2B | ||
| Q1 25 | $2.7B | $1.8B | ||
| Q4 24 | $1.4B | $5.8B | ||
| Q3 24 | $2.2B | $6.1B | ||
| Q2 24 | $1.2B | $-2.4B |
自由现金流率NFLXPFE
| Q1 26 | 41.6% | — | ||
| Q4 25 | 15.5% | 25.6% | ||
| Q3 25 | 23.1% | 24.0% | ||
| Q2 25 | 20.5% | -8.2% | ||
| Q1 25 | 25.2% | 12.9% | ||
| Q4 24 | 13.5% | 32.7% | ||
| Q3 24 | 22.3% | 34.3% | ||
| Q2 24 | 12.7% | -18.2% |
资本支出强度NFLXPFE
| Q1 26 | 1.6% | — | ||
| Q4 25 | 2.0% | 4.8% | ||
| Q3 25 | 1.4% | 3.6% | ||
| Q2 25 | 1.4% | 4.2% | ||
| Q1 25 | 1.2% | 4.1% | ||
| Q4 24 | 1.5% | 5.2% | ||
| Q3 24 | 1.3% | 3.7% | ||
| Q2 24 | 0.8% | 4.8% |
现金转化率NFLXPFE
| Q1 26 | 1.00× | — | ||
| Q4 25 | 0.87× | — | ||
| Q3 25 | 1.11× | 1.30× | ||
| Q2 25 | 0.78× | -0.20× | ||
| Q1 25 | 0.97× | 0.79× | ||
| Q4 24 | 0.82× | 16.39× | ||
| Q3 24 | 0.98× | 1.50× | ||
| Q2 24 | 0.60× | -43.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NFLX
暂无分部数据
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
